Paris saponin II inhibits human ovarian cancer cell-induced angiogenesis by modulating NF-κB signaling

Oncology Reports

Volumn 33, Issue 5, 2015, Pages 2190-2198

  Yang, Mei ^a,b   Zou, Juan ^a   Zhu, Hongmei ^a,b   Liu, Shanling ^a,b   Wang, He ^a,b   Bai, Peng ^b   Xiao, Xue ^a,b,c  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Bcl 2; Bcl xL; NF B; Proliferation; PSII; Tumor angiogenesis; VEGF

Indexed keywords

I KAPPA B ALPHA; I KAPPA B KINASE BETA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PARIS SAPONIN II; PROTEIN BCL 2; PROTEIN BCL XL; SAPONIN; UNCLASSIFIED DRUG; VASCULOTROPIN; ANTINEOPLASTIC AGENT;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; EX VIVO STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; OVARIAN CANCER CELL LINE; OVARY CANCER; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TUMOR GROWTH; WESTERN BLOTTING; ANIMAL; BAGG ALBINO MOUSE; DRUG EFFECTS; FEMALE; GEL MOBILITY SHIFT ASSAY; IMMUNOPRECIPITATION; METABOLISM; MOUSE; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; OVARY TUMOR; PATHOLOGY; TUMOR CELL LINE; TUNEL ASSAY; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CELL LINE, TUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FEMALE; HETEROGRAFTS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPRECIPITATION; IN SITU NICK-END LABELING; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; OVARIAN NEOPLASMS; SAPONINS; SIGNAL TRANSDUCTION;

EID: 84927132877     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.3836     Document Type: Article

References (36)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin 63:11-30, 2013.
2. McGuire WP, Hoskins WJ, Brady MF, et al: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996.
3. Eckstein N: Platinum resistance in breast and ovarian cancer cell lines. J Exp Clin Cancer Res 30:91, 2011.
4. Carmeliet P: Angiogenesis in life, disease and medicine. Nature 438:932-936, 2005.
5. Kerbel RS: Tumor angiogenesis. N Engl J Med 358:2039-2049, 2008.
6. Xu W, Liu LZ, Loizidou M, Ahmed M and Charles IG: The role of nitric oxide in cancer. Cell Res 12:311-320, 2002.
7. Ferrara N and Kerbel RS: Angiogenesis as a therapeutic target. Nature 438:967-974, 2005.
8. Huang S, Robinson JB, Deguzman A, Bucana CD and Fidler IJ: Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res 60:5334-5339, 2000.
9. Aggarwal BB: Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203-208, 2004.
10. Yu HG, Yu LL, Yang Y, et al: Increased expression of RelA/nuclear factor-κB protein correlates with colorectal tumorigenesis. Oncology 65:37-45, 2003.
11. Biswas DK, Shi Q, Baily S, et al: NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 101:10137-10142, 2004.
12. Gilmore TD, Koedood M, Piffat KA and White DW: Rel/NF-kappaB/IkappaB proteins and cancer. Oncogene 13:1367-1378, 1996.
13. Yang G, Xiao X, Rosen DG, et al: The biphasic role of NF-κB in progression and chemoresistance of ovarian cancer. Clin Cancer Res 17:2181-2194, 2011.
14. Scherer DC, Brockman JA, Chen Z, Maniatis T and Ballard DW: Signal-induced degradation of IκBα requires site-specific ubiquitination. Proc Natl Acad Sci USA 92:11259-11263, 1995.
15. Brown K, Gerstberger S, Carlson L, Franzoso G and Siebenlist U: Control of I kappa B-alpha proteolysis by site-specific, signalinduced phosphorylation. Science 267:1485-1488, 1995.
16. Brockman JA, Scherer DC, McKinsey TA, et al: Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol Cell Biol 15:2809-2818, 1995.
17. Huang S, Pettaway CAUH, Bucana CD and Fidler IJ: Blockade of NF-κB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene 20:4188-4197, 2001.
18. Fujioka S, Sclabas GM, Schmidt C, et al: Function of nuclear factor κB in pancreatic cancer metastasis. Clin Cancer Res 9:346-354, 2003.
19. Ho JW, Leung YK and Chan CP: Herbal medicine in the treatment of cancer. Curr Med Chem Anticancer Agents 2:209-214, 2002.
20. Man S, Gao W, Zhang Y, et al: Antitumor and antimetastatic activities of Rhizoma Paridis saponins. Steroids 74:1051-1056, 2009.
21. Cosgrove D: Angiogenesis imaging - ultrasound. Br J Radiol 76(Spec No 1):S43-S49, 2003.
22. Howard-Claudio C: MRI methods for the detection of angiogenesis. Supplement to Appl Radiol: 34, 2005.
23. Man S, Gao W, Zhang Y, et al: Characterization of steroidal saponins in saponin extract from Paris polyphylla by liquid chromatography tandem multi-stage mass spectrometry. Anal Bioanal Chem 395:495-505, 2009.
24. Xiao X, Bai P, Bui Nguyen TM, et al: The antitumoral effect of Paris Saponin I associated with the induction of apoptosis through the mitochondrial pathway. Mol Cancer Ther 8:1179-1188, 2009.
25. Xiao X, Zou J, Bui-Nguyen TM, et al: Paris saponin II of Rhizoma Paridis - a novel inducer of apoptosis in human ovarian cancer cells. Biosci Trends 6:201-211, 2012.
26. Schmitt J and Matei D: Targeting angiogenesis in ovarian cancer. Cancer Treat Rev 38:272-283, 2012.
27. Nicosia RF and Ottinetti A: Growth of microvessels in serum-free matrix culture of rat aorta. A quantitative assay of angiogenesis in vitro. Lab Invest 63:115-122, 1990.
28. Xiao X, Yang M, Xiao J, et al: Paris Saponin II suppresses the growth of human ovarian cancer xenografts via modulating VEGF-mediated angiogenesis and tumor cell migration. Cancer Chemother Pharmacol 73:807-818, 2014.
29. Agbottah E, Yeh WI, Berro R, et al: Two specific drugs, BMS-345541 and purvalanol A induce apoptosis of HTLV-1 infected cells through inhibition of the NF-kappaB and cell cycle pathways. AIDS Res Ther 5:12, 2008.
30. Patan S: Vasculogenesis and angiogenesis. Cancer Treat Res 117:3-32, 2004.
31. Fujioka S, Sclabas GM, Schmidt C, et al: Inhibition of constitutive NF-κB activity by IκBα M suppresses tumorigenesis. Oncogene 22:1365-1370, 2003.
32. Wen F, Yin H, Chen C, et al: Chemical characteristics of saponins from Paris fargesii var. brevipetala and cytotoxic activity of its main ingredient, paris saponin H. Fitoterapia 83:627-635, 2012.
33. Nor JE, Christensen J, Mooney DJ and Polverini PJ: Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 154:375-384, 1999.
34. Nor JE, Christensen J, Liu J, et al: Up-Regulation of Bcl-2 in microvascular endothelial cells enhances intratumoral angiogenesis and accelerates tumor growth. Cancer Res 61:2183-2188, 2001.
35. Karl E, Warner K, Zeitlin B, et al: Bcl-2 acts in a proangiogenic signaling pathway through nuclear factor-κB and CXC chemokines. Cancer Res 65:5063-5069, 2005.
36. Lacouture ME, Lenihan DJ and Quaggin SE (eds): Antiangiogenic Therapy: Tolerability and Management of Side Effects, 2009. (www.angio.org/pdf/Angio-Poster-Final-6-30.pdf).